Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
10 Distinct Kinds of Chinese Neighborhood Specialty Hot Pot - 2Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.'
- 3Europe: 4 Urban communities for a Paramount Social Experience
- 47 Odd Apparatuses to Make Your Party Stick Out!
- 5Which game do you cherish observing live? Vote!
- Santa's sleigh or the International Space Station? How to spot a bright Christmas flyby Dec. 24 and 25
- Attacks on Iran's Bushehr nuclear plant and on Iraq border crossing
- Historic underwater structure discovered by divers off French coast
- RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
- Top 20 Style Brands for Pioneers
- EU agrees on agriculture safeguards as fronts harden in Mercosur deal
- 6 Popular Ladies' Aromas On the planet
- Sound Propensities: 20 Methods for helping Your Insusceptible Framework
- Clocks to go forward one hour in Europe as summer time starts
